| Lipids Management |
1 |
1 |
| Type 2 Diabetes Mellitus |
0 |
0.99 |
| Cardiovascular Risk Management |
0 |
0.86 |
| Chronic Kidney Disease |
0 |
0.54 |
| Renal Failure |
0 |
0.54 |
| Statins |
0 |
0.47 |
| Hypertension |
0 |
0.46 |
| Heart Failure (HF) |
0 |
0.39 |
| Renal Disease |
0 |
0.39 |
| Weight Management |
0 |
0.35 |
| Cardiovascular disease |
0 |
0.31 |
| Kidney |
0 |
0.31 |
| SGLT2 Inhibitor |
0 |
0.31 |
| Weight Loss |
0 |
0.31 |
| LDL Cholesterol |
0 |
0.29 |
| PCSK9 |
0 |
0.27 |
| Blood |
0 |
0.23 |
| Point-of-Care |
0 |
0.23 |
| Clinical Guidelines |
0 |
0.16 |
| Risk Management |
0 |
0.16 |
| Peripheral Artery Disease |
0 |
0.14 |
| Social Determinants of Health |
0 |
0.14 |
| Angiotensin II Receptor Blockade |
0 |
0.11 |
| Cardiovascular Imaging |
0 |
0.11 |
| ACE Inhibitor |
0 |
0.08 |
| Amputation |
0 |
0.08 |
| Board Certification |
0 |
0.08 |
| Ejection Fraction |
0 |
0.08 |
| Heart |
0 |
0.08 |
| Interprofessional Continuing Education |
0 |
0.08 |
| Lipoproteins |
0 |
0.08 |
| Prediabetes |
0 |
0.08 |
| Receptors |
0 |
0.08 |
| Referral |
0 |
0.08 |